Skip to main content

Table 1 Demographic data and clinical characteristics of patients with hepatocellular carcinoma

From: Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis

  Non-cirrhosis n = 200 (%) Cirrhosis n = 2328 (%) P values
Age(mean ± SD) 53.36 ± 11.94 56.96 ± 10.34 < 0.0001
Gender (male) 164 (82.0) 1793 (77.0) 0.106
Family history of HCC 0.005
 Yes 14 (7.0) 74 (3.2)
 No 186 (93.0) 2254 (96.8)
Smoking 0.131
 Smoker 91 (45.5) 932 (40.0)
 Non-smoker 109 (54.5) 1396 (60.0)
Alcohol 0.759
 alcohol 79 (39.5) 894 (38.4)
 No alcohol 121 (60.5) 1434 (61.6)
Diabetes < 0.0001
 Yes 21 (10.5) 506 (21.7)
 No 179 (89.5) 1822 (78.3)
Hypertension 0.81
 Yes 50 (25) 600 (25.8)
 No 150 (75) 1728 (74.2)
Hyperlipidemia 0.002
 Yes 25 (12.5) 154 (6.6)
 No 175 (87.5) 2174 (93.4)
Coronary artery disease 0.918
 Yes 5 (2.5) 61 (2.6)
 No 195 (97.5) 2267 (97.4)
Etiology 0.003
 HBV 153 (76.5) 1823 (78.3)
 HCV 23 (11.5) 177 (7.6)
 Alcohol abuse 10 (5.0) 248 (10.7)
 NAFLD 4 (2.0) 25 (1.1)
 idopathic 10 (5.0) 55 (2.4)
HBeAg at baseline 0.005
 Negative 98 (54.1) 1289 (60.6)
 Positive 45 (24.9) 572 (26.9)
 Missing data 38 (21.0) 265 (12.5)
HBV-DNA at baseline 0.024
 Low(< 500 IU/ml) 71 (41.3) 791 (39.8)
 High(> 500 IU/ml) 63 (36.6) 894 (45.0)
 Missing data 38 (22.1) 301 (15.2)
Antiviral therapy 0.972
 Yes 146 (79.3) 1686 (79.0)
 No 29 (15.8) 348 (16.3)
 Missing data 9 (4.9) 99 (4.6)
Tumor diameter (cm) 3.5 (2.3, 6.2) 3.1 (2.0, 5.7) 0.213
Tumor multiplicity < 0.0001
 solitary 136 (72) 1259 (55.1)
 multiple 53 (28) 1024 (44.9)
PVTT at baseline < 0.0001
 Yes 14 (7.0) 479 (20.6)
 No 186 (93.0) 1849 (79.4)
AFP (ng/ml) 0.754
 AFP < 400 148 (74.0) 1746 (74.9)
 AFP ≥ 400 52 (26.0) 634 (25.1)
BCLC staging < 0.0001
 0-A 106 (53.0) 835 (37.3)
 B 73 (36.5) 734 (31.9)
 C 18 (9.0) 433 (17.8)
 D 3 (1.5) 326 (13.0)
Treatment for HCC 0.002
 Resection 30 (15.0) 185 (7.9)
 Minimally invasive 132 (66.0) 1578 (67.8)
 Palliative 38 (19.0) 565 (24.3)
MELD scores 3.4 (1.29,5.30) 5.39 (2.36,8.48) < 0.0001
Leukocyte counts (109/L) 4.43 (5.71,7.25) 3.05 (4.32,5.90) < 0.0001
NLR 2.19 (1.55,3.68) 2.44 (1.62,3.97) 0.019
Platelets (109/L) 151.8 (112.5197.08) 87.25 (57.23,136.5) < 0.0001
ALT (U/L) 32.1 (22.72,56.7) 33.2 (22.3,54.2) 0.9
AST (U/L) 31.15 (23.8,54.03) 42.4 (28.83,72.13) < 0.0001
Totall Bilirubin (umol/L) 13.4 (9.7,16.98) 19.85 (13.2,32.48) < 0.0001
γ-GGT (U/L) 44.9 (25.9,94.33) 59.35 (33.22,123.8) < 0.0001
Albumin (g/L) 40.09 ± 4.80 35.014 ± 6.34 < 0.0001
Triglyceride (mmol/L) 1.009 ± 0.49 0.87 ± 0.45 < 0.0001
Prothrombin activity (%) 88.77 ± 14.51 75.06 ± 18.00 < 0.0001
Child Staging < 0.0001
 A 177 (88.5) 1125 (48.3)
 B 20 (10.0) 877 (37.7)
 C 3 (1.5) 326 (14.0)
  1. Abbreviations: SD, standard deviation; PVTT, portal vein tumor thrombus; AFP, alpha-fetoprotein; NLR, Neutrophil-lymphocyte ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GGT γ-glutamyl transferase